Loading...
•
Sep 30, 2020
Pacific Biosciences Q3 2020 Earnings Report
Reported increased revenue and progress in key strategic areas.
Key Takeaways
Pacific Biosciences reported increased revenue for Q3 2020, driven by growth in instrument and consumables revenue. The company also made progress in key strategic areas, including the development of new products and expansion of its commercial operations.
Revenue increased to $27.6 million, up from $19.9 million in Q3 2019.
Instrument revenue was $11.8 million, up from $7.1 million in Q3 2019.
Consumables revenue was $13.1 million, up from $10.5 million in Q3 2019.
Net loss was $39.1 million, compared to a net loss of $28.5 million in Q3 2019.
Revenue by Segment
Forward Guidance
Pacific Biosciences anticipates continued growth and innovation.
Positive Outlook
- Expecting continued growth in instrument and consumables revenue.
- Anticipate launch of new products to expand market reach.
- Foresee expansion of commercial operations to support growth.
- Focus on improving gross margin and reducing operating expenses.
- Believe strategic partnerships will drive adoption of SMRT sequencing.
Challenges Ahead
- Uncertainties related to the COVID-19 pandemic could impact results.
- Competition in the sequencing market may affect pricing and demand.
- Dependence on key suppliers for critical components.
- Challenges in scaling up manufacturing to meet demand.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...